Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab in Locally Advanced NSCLC
NCT06734702Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Nov 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06734702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734702.